Phreesia, Inc. (NYSE:PHR – Get Free Report) has been assigned a consensus recommendation of “Hold” from the nineteen brokerages that are covering the company, Marketbeat.com reports. One equities research analyst has rated the stock with a sell recommendation, nine have given a hold recommendation and nine have assigned a buy recommendation to the company. The average 12-month price objective among analysts that have covered the stock in the last year is $16.6471.
PHR has been the subject of a number of analyst reports. Wells Fargo & Company reaffirmed an “equal weight” rating and set a $9.00 target price (down from $15.00) on shares of Phreesia in a research note on Wednesday, May 20th. Citigroup reissued a “market perform” rating on shares of Phreesia in a research report on Friday, May 29th. Wall Street Zen upgraded Phreesia from a “hold” rating to a “buy” rating in a research note on Saturday, May 30th. Piper Sandler lowered Phreesia from an “overweight” rating to a “neutral” rating and set a $12.00 price objective for the company. in a research report on Thursday, May 28th. Finally, Canaccord Genuity Group lowered their price objective on Phreesia from $22.00 to $16.00 and set a “buy” rating for the company in a research note on Thursday, May 28th.
View Our Latest Stock Analysis on Phreesia
Hedge Funds Weigh In On Phreesia
Phreesia Price Performance
PHR opened at $11.47 on Friday. The stock has a fifty day simple moving average of $10.61 and a two-hundred day simple moving average of $10.54. The company has a current ratio of 1.76, a quick ratio of 1.76 and a debt-to-equity ratio of 0.41. The company has a market cap of $709.02 million, a price-to-earnings ratio of 76.47 and a beta of 0.85. Phreesia has a 12-month low of $7.77 and a 12-month high of $32.76.
Phreesia (NYSE:PHR – Get Free Report) last announced its quarterly earnings data on Wednesday, May 27th. The company reported $0.05 EPS for the quarter, beating the consensus estimate of $0.02 by $0.03. Phreesia had a return on equity of 5.13% and a net margin of 1.85%.The business had revenue of $130.94 million during the quarter, compared to analyst estimates of $130.08 million. During the same quarter last year, the firm posted ($0.07) earnings per share. The company’s revenue for the quarter was up 12.9% on a year-over-year basis. Research analysts predict that Phreesia will post 0.39 earnings per share for the current fiscal year.
Phreesia Company Profile
Phreesia, Inc (NYSE: PHR) is a provider of patient intake management solutions designed to streamline front-office workflows for healthcare organizations. The company’s cloud-based platform digitizes patient registration, appointment scheduling, insurance verification, consent documentation and payment collection through touchscreen kiosks, tablets and mobile devices. By replacing paper forms and manual processes, Phreesia enhances data accuracy, reduces administrative burden and improves the patient experience.
Founded in 2000 by Chaim Indig and headquartered in Burlington, Massachusetts, Phreesia offers a modular software suite that integrates with electronic medical record (EMR) and practice management systems.
See Also
- Five stocks we like better than Phreesia
- The AI Boom Is Turning This Cable Maker Into a Stock to Watch
- A Star Investor Just Trimmed Amazon—Here’s What It means
- Wendy’s Deal Buzz May Give Fast-Food Investors a New Reason to Look
- Home Depot Analysts See a Path to $375 and Beyond
Receive News & Ratings for Phreesia Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Phreesia and related companies with MarketBeat.com's FREE daily email newsletter.
